Compare iShares Broad USD Investment Grade Corporate Bond (USIG) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Broad USD Investment Grade Corporate Bond vs State Street SPDR S&P Biotech ETF — how do they compare? iShares Broad USD Investment Grade Corporate Bond trades at $50.51, while State Street SPDR S&P Biotech ETF trades at $154.49. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, iShares Broad USD Investment Grade Corporate Bond nearer its low. Which is the better fit depends on your goals.
| USIG | XBI | |
|---|---|---|
Sector | Fixed Income | Broad Market / Factor |
52-Week High | $52.69 | $164.28 |
52-Week Low | $50.50 | $85.16 |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Broad USD Investment Grade Corporate Bond
USIG is a low-cost ETF providing broad exposure to over 11,000 U.S. investment-grade corporate bonds. It tracks the ICE BofA US Corporate Index, featuring high-quality debt from 2026 leaders like Citigroup, Bank of America, and Oracle.
Read more on USIG →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
